阿达木单抗和生物仿制药治疗中轴性脊柱关节炎患者的药物水平和免疫原性相当 : 来自中国两个中心的回顾性研究.
Mesh : Humans Adalimumab / therapeutic use Biosimilar Pharmaceuticals / therapeutic use adverse effects Retrospective Studies China / epidemiology Female Male Treatment Outcome Adult Axial Spondyloarthritis / diagnosis immunology drug therapy Antirheumatic Agents / therapeutic use Middle Aged Tumor Necrosis Factor Inhibitors / therapeutic use adverse effects
来 源: DOI:10.1111/1756-185X.15190